Porphozym in the Treatment of Acute Attacks in AIP
Status:
Completed
Trial end date:
2006-06-20
Target enrollment:
Participant gender:
Summary
A multi-centre, double-blind, randomized, placebo controlled, parallel group trial,
investigating the efficacy and safety of Porphozym (recombinant human porphobilinogen
deaminase)in the treatment of acute attacks in AIP.